Attenua Inc nabs $35 mln Series A
Attenua Inc, a developer of new chronic cough treatments, has closed $35 million in Series A financing. Omega Funds led the round with participation from investors that included Abingworth, OrbiMed and Redmile Group LLC.
30 April 2018•1 min read
